Aro delivers bispecifics, siRNAs where others can’t

How Aro’s Centyrins can deliver small bispecifics and stable siRNA therapies to penetrate hard-to-reach cancers

A year after its launch, Susan Dillon and Karyn O’Neil’s Aro has begun to reveal details about how the J&J spinout’s Centyrins could form small bispecifics and stable siRNA therapies to penetrate hard-to-reach cancers.

Therapies built from the Centyrin protein scaffold could have more potency than monoclonals to penetrate tumors, and the platform also has the potential to deliver oligonucleotides to tissues outside the liver.

Johnson & Johnson veterans Dillon and O’Neil founded Aro Biotherapeutics Co. in January 2018 with an exclusive worldwide license for Centyrins, with an exception

Read the full 888 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE